TD Cowen analyst Yaron Werber has maintained their bullish stance on RARE stock, giving a Buy rating on February 6.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Yaron Werber’s rating is based on several encouraging factors for Ultragenyx Pharmaceutical. The company reported strong sales in the fourth quarter for its key products, Crysvita and Dojolvi, with significant year-over-year growth. Management has confirmed the fiscal year 2025 revenue guidance, which suggests robust revenue growth and highlights the company’s financial health. Furthermore, the company’s focus on reducing net cash spending indicates efficient financial management.
In addition to the solid financial performance, the potential for future success is supported by multiple upcoming high-profile data releases from its clinical-stage pipeline. The anticipated positive outcomes from the Phase 3 Orbit analyses and other clinical studies, such as the ASPIRE study in AS and the PDUFA launch for UX111, are critical factors in this optimistic outlook. These developments are expected to drive the company’s shares and set a path toward full GAAP profitability by 2027, reinforcing the Buy rating.
In another report released on February 6, Morgan Stanley also maintained a Buy rating on the stock with a $64.00 price target.
Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RARE in relation to earlier this year.